Pharma Focus Europe

GBI Enhances Its Position in Radiopharmaceutical Manufacturing Through the Acquisition of a New Contract for Commercial Manufacturing

Wednesday, January 10, 2024

GBI BioManufacturing, formerly recognized as Goodwin Biotechnology, is excited to announce the completion of its second master supply agreement for the commercialization of a radioimmunoconjugate product. This significant milestone not only underscores our dedication to advancing healthcare through cutting-edge radiopharmaceuticals in collaboration with our clients but also solidifies our standing as a reliable partner in the integrated Contract Development and Manufacturing Organization (CDMO) biologic space, equipped with the expertise to navigate a product's journey from clinical trials to commercialization.

Darrin Schellin, the CEO, expressed his enthusiasm, stating, "We are thrilled to announce the signing of our second commercial contract, a testament to the exceptional capabilities and unwavering commitment of the entire GBI team." This success showcases our proficiency and experience in the radiopharmaceutical sector, emphasizing the trust our clients place in us.

As the demand for radiopharmaceuticals continues to surge, GBI is well-equipped to meet customer needs through substantial investments in advanced development and manufacturing capabilities.

Karl Pinto, Chairman of the Board of Directors of GBI, added, "We are pleased to see new customers entrust us with their long-term commercial product needs." This announcement highlights the robust, enduring, and strategic nature of our partnership with this burgeoning global radiopharmaceutical leader. The radiopharmaceutical sector is undergoing unprecedented growth, and GBI takes pride in being at the forefront of this transformative industry.

 

Source: prnewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva